A number of phase 3 trials (Check‐Mate‐017/‐057, KEYNOTE‐042/‐189) have shown that nivolumab or pembrolizumab monotherapy produces prolonged OS benefits in NSCLC beyond chemotherapy, irrespective of PD‐L1 expression level.6, 7, 26. Here, CD274 is linked to non-small cell lung carcinoma.